Our results uncover the pro-oncogenic effect of FBXO9 in HCC and demonstrate that the ZNF143–FBXO9–FBXW7 regulatory pathway is a prospective target for anti-HCC treatment. This evidence concerns the gene FBXW7 and hepatocellular carcinoma.